November 28, 2022Open Access
IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Efficacy benefits were observed with atezolizumab + bevacizumab in patients with baseline BCLC stage B disease, consistent with the intention-to-treat population.
Cite This Study
Kudo et al. (Mon,) studied this question.